BTIG Research Boosts Glaukos (NYSE:GKOS) Price Target to $202.00

Glaukos (NYSE:GKOS) had its price objective upped by BTIG Research from $193.00 to $202.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the medical instruments supplier’s stock. BTIG Research’s price target indicates a potential upside of 6.47% from the company’s current price.

Other analysts have also issued reports about the company. Stifel Nicolaus raised their price objective on Glaukos from $175.00 to $190.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. William Blair reissued an “outperform” rating on shares of Glaukos in a research note on Tuesday, May 26th. Citigroup increased their target price on shares of Glaukos from $175.00 to $188.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Wells Fargo & Company raised their price target on shares of Glaukos from $138.00 to $178.00 and gave the company an “overweight” rating in a research note on Thursday, July 30th. Finally, UBS Group began coverage on shares of Glaukos in a report on Tuesday, July 28th. They set a “neutral” rating and a $150.00 price target on the stock. Twelve analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $178.08.

Glaukos Stock Performance

Shares of NYSE:GKOS opened at $189.72 on Thursday. Glaukos has a 1 year low of $73.16 and a 1 year high of $190.06. The stock has a market capitalization of $11.19 billion, a price-to-earnings ratio of -58.38 and a beta of 0.78. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.04 and a quick ratio of 4.46. The company’s 50 day simple moving average is $154.98 and its 200 day simple moving average is $130.78.

Glaukos (NYSE:GKOS) last released its earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.07. The firm had revenue of $185.61 million during the quarter, compared to analysts’ expectations of $150.93 million. Glaukos had a negative return on equity of 6.37% and a negative net margin of 30.68%.The company’s quarterly revenue was up 49.6% on a year-over-year basis. During the same period in the prior year, the company earned ($0.24) earnings per share. As a group, research analysts predict that Glaukos will post -0.35 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Alex R. Thurman sold 20,000 shares of Glaukos stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $180.13, for a total transaction of $3,602,600.00. Following the sale, the chief financial officer directly owned 43,906 shares of the company’s stock, valued at approximately $7,908,787.78. This trade represents a 31.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Joseph E. Gilliam sold 60,000 shares of the business’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $179.74, for a total value of $10,784,400.00. Following the sale, the chief operating officer owned 72,588 shares in the company, valued at approximately $13,046,967.12. This trade represents a 45.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 110,525 shares of company stock worth $19,125,006 in the last 90 days. Insiders own 5.90% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Wealth Alliance LLC grew its holdings in Glaukos by 4.5% during the 1st quarter. Wealth Alliance LLC now owns 2,297 shares of the medical instruments supplier’s stock worth $247,000 after acquiring an additional 98 shares during the last quarter. Smartleaf Asset Management LLC raised its stake in shares of Glaukos by 9.7% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,383 shares of the medical instruments supplier’s stock valued at $158,000 after acquiring an additional 122 shares during the last quarter. Larson Financial Group LLC lifted its holdings in shares of Glaukos by 62.0% during the fourth quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock worth $39,000 after purchasing an additional 132 shares during the period. CWM LLC lifted its holdings in shares of Glaukos by 25.2% during the fourth quarter. CWM LLC now owns 710 shares of the medical instruments supplier’s stock worth $80,000 after purchasing an additional 143 shares during the period. Finally, Commonwealth Equity Services LLC grew its stake in shares of Glaukos by 1.7% in the fourth quarter. Commonwealth Equity Services LLC now owns 8,383 shares of the medical instruments supplier’s stock worth $947,000 after purchasing an additional 144 shares during the last quarter. Institutional investors own 99.04% of the company’s stock.

More Glaukos News

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Zacks Research raised multiple long-term EPS forecasts. Estimates increased for FY2027 EPS to $0.45 from $0.38, FY2028 EPS to $1.70 from $1.56, Q4 2027 EPS to $0.33 from $0.30, Q1 2028 EPS to $0.18 from $0.16, and Q2 2028 EPS to $0.37 from $0.32. The revisions suggest stronger expected profitability as Glaukos scales its business. Zacks Research article
• Positive Sentiment: Growth catalysts remain intact. Zacks highlighted Glaukos’ iDose TR and Epioxa products, margin-expansion potential, and broad development pipeline as reasons to retain the stock. These factors support the long-term growth narrative behind GKOS.
• Neutral Sentiment: Management will participate in the Wells Fargo Healthcare Conference on September 9, 2026. The event could provide updates on product launches, clinical programs, and financial goals, although no new operating information was announced. Glaukos Wells Fargo Healthcare Conference announcement
• Negative Sentiment: One near-term estimate was reduced. Zacks lowered its Q2 2027 EPS forecast to $0.06 from $0.07, indicating some modest pressure in the intermediate outlook. However, the cut was outweighed by increases to most other quarterly and annual forecasts.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.